Review
Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase
Affiliations
- PMID: 9236856
Item in Clipboard
Review
Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase
Anticancer Drug Des.
1997 Jul.
No abstract available
Similar articles
-
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.Clin Cancer Res. 2002 Aug;8(8):2530-5. Clin Cancer Res. 2002. PMID: 12171880 Clinical Trial.
-
Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.Cancer Res. 1996 Aug 1;56(15):3499-507. Cancer Res. 1996. PMID: 8758918
-
First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies.Anticancer Drug Des. 1997 Jul;12(5):327-39. Anticancer Drug Des. 1997. PMID: 9236850 Review. No abstract available.
-
Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.Curr Opin Mol Ther. 1999 Jun;1(3):372-85. Curr Opin Mol Ther. 1999. PMID: 11713802 Review.
-
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.Drug Metab Dispos. 1997 Nov;25(11):1272-81. Drug Metab Dispos. 1997. PMID: 9351904
Cited by
-
Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant.Antimicrob Agents Chemother. 1999 Feb;43(2):347-53. doi: 10.1128/AAC.43.2.347. Antimicrob Agents Chemother. 1999. PMID: 9925530 Free PMC article.
-
Chemical Modification of CRISPR gRNAs Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells.J Cytokine Biol. 2018;3(1):121. doi: 10.4172/2576-3881.1000121. Epub 2018 Jan 29. J Cytokine Biol. 2018. PMID: 30225466 Free PMC article.
-
Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Gene Regul Syst Bio. 2008 Sep 22;2:275-95. doi: 10.4137/grsb.s418. Gene Regul Syst Bio. 2008. PMID: 19787090 Free PMC article.
-
A cytosine analog that confers enhanced potency to antisense oligonucleotides.Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3513-8. doi: 10.1073/pnas.96.7.3513. Proc Natl Acad Sci U S A. 1999. PMID: 10097067 Free PMC article.
-
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.Invest New Drugs. 2005 Oct;23(5):467-77. doi: 10.1007/s10637-005-2906-0. Invest New Drugs. 2005. PMID: 16133798 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous